

PHARMACY BENEFIT PRIOR AUTHORIZATION UPDATES

3/21/2025

Below are upcoming updates to pharmacy benefit medication prior authorization criteria for Community Health Choice's Marketplace plans.

Marketplace Premier Plans

Drug/Class	Effective Date	Overview
Prevymis pellet pak	4/1/2025	Adding to formulary with PA
Calquence tab	4/1/2025	Adding new indication in combination with bendamustine & rituximab for patients with previously untreated mantle cell lymphoma (MCL)
Cimzia	4/1/2025	Updating step through criteria for rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA) - removing adalimumab + tocilizumab pathway; adding tocilizumab as preferred option
Kevzara	4/1/2025	Updating step through criteria for rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA) - removing adalimumab + tocilizumab pathway; adding tocilizumab to preferred agents
Olumiant	4/1/2025	Updating rheumatoid arthritis (RA) step through criteria - removing adalimumab + tocilizumab pathway; adding tocilizumab as preferred agent
Orencia	4/1/2025	Updating rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA) step through criteria - removing adalimumab + tocilizumab pathway; adding tocilizumab as preferred option
Tyenne	4/1/2025	Moving tocilizumab into preferred positioning for rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA)

Marketplace Select Plans

Drug/Class	Effective Date	Overview
Prevymis pellet pak	4/1/2025	Adding to formulary with PA
Calquence tab	4/1/2025	Adding new indication in combination with bendamustine & rituximab for patients with previously untreated mantle cell lymphoma (MCL)
Cimzia	4/1/2025	Updating step through criteria for rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA) - removing adalimumab + tocilizumab pathway; adding tocilizumab as preferred option
Tyenne	4/1/2025	Moving tocilizumab into preferred positioning for rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA)